» Articles » PMID: 38067494

Insights into the Current and Possible Future Use of Opioid Antagonists in Relation to Opioid-Induced Constipation and Dysbiosis

Overview
Journal Molecules
Publisher MDPI
Specialty Biology
Date 2023 Dec 9
PMID 38067494
Authors
Affiliations
Soon will be listed here.
Abstract

Opioid receptor agonists, particularly those that activate µ-opioid receptors (MORs), are essential analgesic agents for acute or chronic mild to severe pain treatment. However, their use has raised concerns including, among others, intestinal dysbiosis. In addition, growing data on constipation-evoked intestinal dysbiosis have been reported. Opioid-induced constipation (OIC) creates an obstacle to continuing treatment with opioid analgesics. When non-opioid therapies fail to overcome the OIC, opioid antagonists with peripheral, fast first-pass metabolism, and gastrointestinal localized effects remain the drug of choice for OIC, which are discussed here. At first glance, their use seems to only be restricted to constipation, however, recent data on OIC-related dysbiosis and its contribution to the appearance of several opioid side effects has garnered a great of attention from researchers. Peripheral MORs have also been considered as a future target for opioid analgesics with limited central side effects. The properties of MOR antagonists counteracting OIC, and with limited influence on central and possibly peripheral MOR-mediated antinociception, will be highlighted. A new concept is also proposed for developing gut-selective MOR antagonists to treat or restore OIC while keeping peripheral antinociception unaffected. The impact of opioid antagonists on OIC in relation to changes in the gut microbiome is included.

Citing Articles

Roles of the gut microbiota in human neurodevelopment and adult brain disorders.

Mallick R, Basak S, Das R, Banerjee A, Paul S, Pathak S Front Neurosci. 2024; 18:1446700.

PMID: 39659882 PMC: 11628544. DOI: 10.3389/fnins.2024.1446700.


Glycine Transporter 1 Inhibitors Minimize the Analgesic Tolerance to Morphine.

Galambos A, Essmat N, Lakatos P, Szucs E, Boldizsar Jr I, Abbood S Int J Mol Sci. 2024; 25(20).

PMID: 39456918 PMC: 11508341. DOI: 10.3390/ijms252011136.


Opioid Use and Gut Dysbiosis in Cancer Pain Patients.

Coluzzi F, Scerpa M, Loffredo C, Borro M, Pergolizzi J, LeQuang J Int J Mol Sci. 2024; 25(14).

PMID: 39063241 PMC: 11276997. DOI: 10.3390/ijms25147999.


The interplay between the microbiota and opioid in the treatment of neuropathic pain.

Gong Z, Xue Q, Luo Y, Yu B, Hua B, Liu Z Front Microbiol. 2024; 15:1390046.

PMID: 38919504 PMC: 11197152. DOI: 10.3389/fmicb.2024.1390046.


Long-Term Implicit Epigenetic Stress Information in the Enteric Nervous System and its Contribution to Developing and Perpetuating IBS.

Noemi C, Bob P, Bokkon I Curr Neuropharmacol. 2024; 22(13):2100-2112.

PMID: 38726788 PMC: 11337685. DOI: 10.2174/1570159X22666240507095700.


References
1.
Greig S, Keating G . Naltrexone ER/Bupropion ER: A Review in Obesity Management. Drugs. 2015; 75(11):1269-80. DOI: 10.1007/s40265-015-0427-5. View

2.
Henriksen G, Willoch F . Imaging of opioid receptors in the central nervous system. Brain. 2007; 131(Pt 5):1171-96. PMC: 2367693. DOI: 10.1093/brain/awm255. View

3.
Khalefa B, Shaqura M, Al-Khrasani M, Furst S, Mousa S, Schafer M . Relative contributions of peripheral versus supraspinal or spinal opioid receptors to the antinociception of systemic opioids. Eur J Pain. 2012; 16(5):690-705. DOI: 10.1002/j.1532-2149.2011.00070.x. View

4.
Moriarty O, Ruane N, OGorman D, Maharaj C, Mitchell C, Sarma K . Cognitive Impairment in Patients with Chronic Neuropathic or Radicular Pain: An Interaction of Pain and Age. Front Behav Neurosci. 2017; 11:100. PMC: 5468384. DOI: 10.3389/fnbeh.2017.00100. View

5.
Yuan C, Foss J, Moss J . Effects of methylnaltrexone on morphine-induced inhibition of contraction in isolated guinea-pig ileum and human intestine. Eur J Pharmacol. 1995; 276(1-2):107-11. DOI: 10.1016/0014-2999(95)00018-g. View